Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | Chief Strategy Officer | April 01, 2022 | April 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date April 01, 2022 · Filed April 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 158,684 |
Reported balance
After 2022-04-01 transaction · row 1
1 source rowRow 1 · 2022-04-01 · Grant · Acquired 82,305 · Balance 158,684 F1: On April 1, 2022, Mr. Brown was granted 82,305 restricted stock awards. These awards vest on the first anniversary date of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.33 · Expires 2027-03-02 | Direct | 45,017 |
Reported balance
Holding disclosure · report date 2022-04-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 45,017 F2: On March 2, 2020, Mr. Brown was granted 45,017 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.17 · Expires 2028-03-02 | Direct | 26,378 |
Reported balance
Holding disclosure · report date 2022-04-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 26,378 F3: On March 2, 2021, Mr. Brown was granted 26,378 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.41 · Expires 2029-03-01 | Direct | 85,519 |
Reported balance
Holding disclosure · report date 2022-04-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 85,519 F4: On March 1, 2022, Mr. Brown was granted 85,519 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 1, 2022, Mr. Brown was granted 82,305 restricted stock awards. These awards vest on the first anniversary date of the grant date.
F2: On March 2, 2020, Mr. Brown was granted 45,017 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F3: On March 2, 2021, Mr. Brown was granted 26,378 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F4: On March 1, 2022, Mr. Brown was granted 85,519 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2022 Filed Apr 4, 2022 23:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 82,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000054 · wf-form4_164911361608506.xml · nonDerivative · entry 1 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,684 F1 · shares: On April 1, 2022, Mr. Brown was granted 82,305 restricted stock awards. These awards vest on the first anniversary date of the grant date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 00:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 867 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000039 · wf-form4_164635540556006.xml · nonDerivative · entry 2 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,379 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2022 vesting of restricted stock. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 85,519 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001077183-22-000039 · wf-form4_164635540556006.xml · derivative · entry 5 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,519 Underlying: Common Stock · 85,519 shares Expires 2029-03-01 F5 · derivative.exercise_date: On March 1, 2022, Mr. Brown was granted 85,519 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 35,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000039 · wf-form4_164635540556006.xml · nonDerivative · entry 1 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,246 F1 · shares: On March 1, 2022, Mr. Brown was granted 35,030 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| December 30, 2021 Filed Dec 30, 2021 23:02 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 30,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000271 · wf-form4_164090533233635.xml · nonDerivative · entry 1 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,216 F1 · kind: On December 30, 2021, Mr. Brown was granted 30,572 restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022. Read SEC document |
| November 26, 2021 Filed Nov 26, 2021 21:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 33,334 | $36.85 | $1,228,357.90 |
DisclosureSEC source: 0001077183-21-000249 · wf-form4_163796128276463.xml · nonDerivative · entry 3 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,644 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 24, 2021 Filed Nov 26, 2021 21:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 33,333 | $36.84 | $1,227,987.72 |
DisclosureSEC source: 0001077183-21-000249 · wf-form4_163796128276463.xml · nonDerivative · entry 2 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,978 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 21:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 33,333 | $37.19 | $1,239,654.27 |
DisclosureSEC source: 0001077183-21-000249 · wf-form4_163796128276463.xml · nonDerivative · entry 1 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,311 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 02:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 26,378 | $53.17 Strike: $53.17 | $1,402,518.26 |
DisclosureSEC source: 0001077183-21-000089 · wf-form4_161490996623773.xml · derivative · entry 3 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,378 Underlying: Common Stock · 26,378 shares Expires 2028-03-02 F2 · derivative.exercise_date: On March 2, 2021, Mr. Brown was granted 26,378 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 02:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 4,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000089 · wf-form4_161490996623773.xml · nonDerivative · entry 1 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,644 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.